Press Release FeedGet the RSS feed
Menu

Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

1,025 resultsPage 69 of 86, newest first
  1. FinanceThe Government of CanadaKardium Receives Funding From the Government of Canada to Expand Manufacturing of the Globe® Pulsed Field System in British ColumbiaVANCOUVER, British Columbia, August 27, 2026--The Government of Canada today announced funding of up to $31.25 million through the Strategic Response Fund (SRF) toward Kardium’s investment in a $125 million project to expand its manufacturing capabilities in Vancouver, British Columbia.
  2. IndustrialConfirming the Relevance of AFYREN’s Business Model and Advancing the Industrial Production Ramp-upCLERMONT-FERRAND, France & LYON, France, August 27, 2026--Regulatory News: AFYREN, a greentech company offering manufacturers biobased, low-carbon ingredients through a unique fermentation technology based on a circular model, provides an update on the operational performance of its AFYREN NEOXY plant and shares its outlook for the second half of 2026.
  3. AIThe World's Leading Minds in Biotechnology Will Meet in Riyadh This SeptemberRIYADH, KSA, Aug 28, 2026 - The Riyadh Global Medical Biotechnology Summit has published the scientific program for its fourth edition, and the names on it belong to the people currently deciding what medicine will be able to do in the next twenty years. Sixty confirmed speakers and moderators from eleven countries are named across three days, from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Convention Centre. Among them are Prof. Jin-Soo Kim of KAIST, whose work on mitochondrial DNA editing reaches beyond CRISPR; Dr. Matthew H. Porteus of Stanford University, engineering genetic circuits into cell-based medicines; Dr. Alex Shalek of MIT; Prof. Vijay Kuchroo of Harvard Medical School; Prof. Keith T. Flaherty of the Massachusetts General Hospital Cancer Center and President of the American Association for Cancer Research; Prof. George F. Gao of the Chinese Academy of Sciences; President Mitsuo Ochi of Hiroshima University; and Dr. Zdenko Herceg of the International Agency for Research on Cancer. They are joined by the people who move science into the world. Dr. Steve Yang, Co-CEO of WuXi AppTec, and Mr. Alec Reynolds of Flagship Pioneering open the program on global partnership. Mr. Kasim Kutay, Chief Executive Officer of Novo Holdings, speaks on where capital should go next. Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, delivers the closing keynote. Alongside them stand the Saudi institutions building a biotechnology sector in real time: KAIMRC, Lifera, HUMAIN, SPIMACO, KAUST, the Saudi Food and Drug Authority, and Astronaut Rayyanah Barnawi on what the human immune system does in space. The program runs across six tracks: artificial intelligence in biotechnology, multi-omics, biotech investment, immunology, bioengineering and synthetic biology, and biotech workforce development. Its defining feature is that discovery and delivery share the same stage. Genome editing and population genomics sit beside regulation, domestic manufacturing, and procurement, and in several sessions the scientists and the regulators are on the same panel. That is the premise of the Kingdom's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040: a discovery is worth only as much as the system available to carry it to a patient. "Biotechnology is where the health of every nation will be decided over the next twenty years. Saudi Arabia has chosen not to watch that happen from a distance. We are building the laboratories, the manufacturing, the regulatory ecosystems, and above all, the bio-workforce talent. And we are building it in partnership with the world, under one roof. That is what this Summit is for. Its themes highlight where medicine and biotechnology converge to shape the future of biosciences. Discoveries and breakthroughs are transforming how we care for patients. The diversity of emerging technologies and therapies is creating significant opportunities to explore, advance, invest, and translate scientific progress into better health outcomes. Please join us in Riyadh this September." H.E. Prof. Bandar bin Abdulmohsen Al-Knawy, Chief Executive Officer of Health Affairs, Ministry of National Guard, and President, King Saud bin Abdulaziz University for Health Sciences The Summit is organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment and Invest Saudi serving as strategic partners. The fourth edition is expected to welcome more than 15,000 visitors, over 200 biotechnology and healthcare brands, and delegations from more than 70 countries, under the theme Building the Foundations of Biotechnology Excellence. The full scientific program is attached and available at rgmbs.org, where registration is open for delegates, exhibitors, and industry partners. Follow the Summit at #RGMBS2026. For further information regarding summit programing visit: https://rgmbs.org/program#conference-agenda About the Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition takes place from 14 to 16 September 2026 in Riyadh. For Media Inquiry Email: [email protected] Telephone: +966 559 810 777
  4. FinanceOverseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New OpportunitiesCanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately RMB 550 million, up 43.8% year on year, while its net loss attributable to shareholders narrowed significantly. Notably, while demand in China’s vaccine market remains challenging, CanSinoBIO’s international business maintained strong growth momentum, generating overseas revenue of RMB 150 million during the reporting period. As established products accelerate their expansion into overseas markets, and collaboration models such as technology partnerships and localized industrialization continue to take shape, CanSinoBIO’s overseas business is evolving from a strategic initiative into an increasingly important contributor to the Company’s performance. This reflects the Company’s forward-looking understanding of global vaccine market trends and evolving demand in international markets. At a time when the vaccine industry is facing changes in demand structure, the combination of domestic innovation capabilities and access to international markets is becoming an increasingly important measure of corporate growth resilience. Overseas Growth Accelerates In the first half of 2026, China’s vaccine industry continued to face demand-side pressure. As the target population for infant and young-child vaccination continues to decline, demand pressure on traditional pediatric vaccines has become increasingly visible. “Volume contraction and price decline” has emerged as a widespread challenge across the industry. Based on disclosed financial results across the sector, this pressure appears to be industry-wide. In 2025, Zhifei Biological generated RMB1.187 billion in revenue from self-developed products, up 1.23% year on year. Walvax Biotechnology reported 2025 revenue of RMB2.418 billion, down 14.29% year on year; despite a 53.36% year-on-year increase in batch-release volume for its core 13-valent pneumococcal conjugate vaccine, revenue remained under pressure. Kangtai Biological reported revenue of RMB1.273 billion in the first half of 2026, down 8.55% year on year. Against this industry backdrop, the growth of CanSinoBIO’s international business is particularly noteworthy. The Company reported overseas revenue of RMB 150 million in the first half of 2026. This growth was driven, on the one hand, by the continued expansion of mature products into overseas markets and, on the other, by the further deepening of the Company’s international partnership models. For CanSinoBIO, this also means that its products, manufacturing processes and quality control capabilities, validated in the domestic market, are beginning to unlock value overseas through more diversified approaches. Meanwhile, the Company continues to advance its international market footprint. Registration filings and commercialization efforts remain underway across Southeast Asia, South America and the Middle East. Menhycia(R) has obtained registration approvals in Indonesia and Argentina, and product supply has already commenced in Indonesia. As more products progress through overseas registration and commercialization, CanSinoBIO’s international business is expected to develop more diversified revenue streams and further strengthen its commercial resilience. From this perspective, CanSinoBIO’s globalization strategy is evolving. Overseas markets are no longer merely destinations for mature products, but are increasingly becoming markets in which products, technologies and industrial capabilities can jointly create value. For an innovative vaccine company, this shift from “exporting products” to “exporting capabilities and systems” creates greater room for long-term growth in its overseas business. Portfolio Upgrades Strengthen the Commercial Foundation Sustained overseas expansion is underpinned by a stable product portfolio and strong technological capabilities. According to the Company’s interim report, domestic revenue continued to grow despite factors such as changes in value-added tax, reflecting opportunities created by ongoing innovation. Menhycia(R), China’s first quadrivalent meningococcal conjugate vaccine, expanded its indicated population in February to children aged 3 months to 6 years, broadening its addressable population. Meanwhile, iPneucia(R), a 13-valent pneumococcal conjugate vaccine featuring dual-carrier technology (CRM197/TT), offers a differentiated option for pediatric pneumococcal disease prevention in China. Since its launch in September 2025, iPneucia(R) has continued to expand market access and is now available in nearly 30 provincial-level markets across China. From meningococcal disease to pneumococcal disease, CanSinoBIO is using innovative products to address vaccine segments that continue to offer meaningful unmet demand. As traditional vaccine categories face pressure on volumes, structural growth driven by product and technology upgrades is providing important support for the Company’s commercial resilience. More importantly, the product-development and industrialization capabilities established in the domestic market also provide a foundation for overseas expansion. For an innovative vaccine company, successful commercialization in China not only broadens revenue sources, but also validates the manufacturing, quality-control and supply systems required to replicate and extend those capabilities into international markets. Domestic product upgrades and overseas business growth are thereforeclosely connected rather than separate. The former provides the foundation in products and technologies, while the latter expands the geographic boundaries within which those products can realize their value. Multi-Layered Pipeline Takes Shape to Support Future Growth For an innovative vaccine company, long-term growth depends not only on the commercial performance of existing products, but also on the ability to maintain a steady flow of new products. By pursuing continued ramp-up of marketed products, advancing products under regulatory review and developing next-generation candidates, CanSinoBIO is building a more sustainable and well-sequenced product pipeline. Tripecia(R) (DT3cP Infant), CanSinoBIO’s three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received NDA approval in April 2026, becoming the first approved three-component DTP vaccine in China. In August 2026, the first commercial batches received the Certificate for Batch Release of Biological Products. Provincial tendering and market-access processes are progressing in an orderly manner, and the product has begun entering the market supply stage. While Tripecia(R) represents an upgrade in pertussis vaccination for infants, the Td5cp vaccine for adolescents and adults — which has also been granted Priority Review status — is expected to extend CanSinoBIO’s pertussis vaccine portfolio to a broader population. The New Drug Application for Td5cp has been accepted by China’s National Medical Products Administration (NMPA). In addition, CanSinoBIO’s independently developed Adsorbed Tetanus Vaccine, Tetcia(R), has been formally approved, further strengthening the Company’s adult vaccine portfolio. From infants to adolescents and adults, and from individual products to a multi-product portfolio, this strategy is broadening the foundation for future commercial growth. In pneumococcal vaccines, CanSinoBIO’s 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV24) formally initiated Phase I/II clinical trials in May 2026, and participant enrollment across different cohorts is progressing as planned. At the same time, the Company continues to advance development of its DT3cP-Hib-MCV4 combination vaccine, extending its portfolio toward increasingly multivalent and combination vaccine formats. Over the longer term, CanSinoBIO is continuing to build its mRNA platform and explore applications in preventive vaccines and therapeutic biologics. The Company is conducting early-stage research into mRNA applications for glioblastoma, rhabdomyosarcoma and cervical cancer, while also exploring in vivo CAR therapies. These programs remain at an early stage, with the Company continuing to assess the potential of mRNA and related technologies in disease treatment. Additionally, on August 25, CanSinoBIO announced that its subsidiary, CanSino Shanghai, had entered a strategic collaboration with deepGeneAI on mRNA therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the development and commercialization of personalized mRNA therapeutic cancer vaccines. These pipeline programs represent extensions of CanSinoBIO’s existing technology platforms and product-development experience. The Company’s core platforms — including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, as well as formulation and delivery technologies — provide a foundation for continued product iteration and technology translation. Innovation Supports Long-Term Development Viewed in the context of its 2026 interim results, CanSinoBIO’s story is not simply one of revenue growth. Against a changing domestic vaccine demand structure, innovative products have continued to deliver solid commercial performance, demonstrating the resilience created by product upgrades. Overseas business model expanded beyond finished-product exports to include technology collaboration and local manufacturing capabilities, indicating that international markets are becoming a new source of growth. At the same time, Tripecia(R) has entered the market supply stage, the Td5cp vaccine for adolescents and adults is progressing through regulatory review, and pipeline programs including PCV24, multivalent and combination vaccines, and mRNA technologies continue to advance, providing both product succession and technology reserves for the future. These three pathways ultimately point to the same growth logic: domestic innovation capabilities form the product foundation, overseas expansion broadens the commercial opportunity, and sustained R&D determines whether growth can continue over the long term. In an environment where demand for traditional vaccines is under pressure and industry competition is intensifying, growth is increasingly shifting away from reliance on product-volume expansion alone and toward a model jointly driven by product upgrades, technological innovation and global markets. For CanSinoBIO, continued growth in the overseas business is providing increasingly visible financial evidence of this transition. As more innovative products enter the market, more mature products expand overseas and the Company’s technical capabilities extend further into international value chains, CanSinoBIO’s growth runway is expanding from a single domestic market to the global market. For the Company, internationalization is not only about broadening geographic reach; it is also an important pathway for innovative products and technologies to realize greater commercial value while contributing to global public health.
  5. FinanceNexteer; Phoenix InvestorsPHOENIX INVESTORS AND NEXTEER AUTOMOTIVE ANNOUNCE COMPLETION OF 1.8 MILLION-SQUARE-FOOT, THREE-BUILDING INDUSTRIAL PROPERTY TRANSACTION IN SAGINAW, MICHIGANAcquisition supports Nexteer's continued manufacturing operations while creating significant new investment, redevelopment, and leasing opportunities in Buena Vista Charter Township — An affiliate of Milwaukee-based Phoenix Investors...
  6. FinanceRTXRTX's Raytheon completes $50 million expansion of Mississippi manufacturing facilityCompanies: RTXExpansion to boost production capacity for critical defense systems and create 100 high-skill jobs — Raytheon, an RTX (NYSE: RTX) business, has completed a 17,000 square-foot expansion of its Forest, Mississippi manufacturing facility. Supported...
  7. FinanceOverseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New OpportunitiesCanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately RMB 550 million, up 43.8% year on year, while its net loss attributable to shareholders narrowed significantly. Notably, while demand in China’s vaccine market remains challenging, CanSinoBIO’s international business maintained strong growth momentum, generating overseas revenue of RMB 150 million during the reporting period. As established products accelerate their expansion into overseas markets, and collaboration models such as technology partnerships and localized industrialization continue to take shape, CanSinoBIO’s overseas business is evolving from a strategic initiative into an increasingly important contributor to the Company’s performance. This reflects the Company’s forward-looking understanding of global vaccine market trends and evolving demand in international markets. At a time when the vaccine industry is facing changes in demand structure, the combination of domestic innovation capabilities and access to international markets is becoming an increasingly important measure of corporate growth resilience. Overseas Growth Accelerates In the first half of 2026, China’s vaccine industry continued to face demand-side pressure. As the target population for infant and young-child vaccination continues to decline, demand pressure on traditional pediatric vaccines has become increasingly visible. “Volume contraction and price decline” has emerged as a widespread challenge across the industry. Based on disclosed financial results across the sector, this pressure appears to be industry-wide. In 2025, Zhifei Biological generated RMB1.187 billion in revenue from self-developed products, up 1.23% year on year. Walvax Biotechnology reported 2025 revenue of RMB2.418 billion, down 14.29% year on year; despite a 53.36% year-on-year increase in batch-release volume for its core 13-valent pneumococcal conjugate vaccine, revenue remained under pressure. Kangtai Biological reported revenue of RMB1.273 billion in the first half of 2026, down 8.55% year on year. Against this industry backdrop, the growth of CanSinoBIO’s international business is particularly noteworthy. The Company reported overseas revenue of RMB 150 million in the first half of 2026. This growth was driven, on the one hand, by the continued expansion of mature products into overseas markets and, on the other, by the further deepening of the Company’s international partnership models. For CanSinoBIO, this also means that its products, manufacturing processes and quality control capabilities, validated in the domestic market, are beginning to unlock value overseas through more diversified approaches. Meanwhile, the Company continues to advance its international market footprint. Registration filings and commercialization efforts remain underway across Southeast Asia, South America and the Middle East. Menhycia(R) has obtained registration approvals in Indonesia and Argentina, and product supply has already commenced in Indonesia. As more products progress through overseas registration and commercialization, CanSinoBIO’s international business is expected to develop more diversified revenue streams and further strengthen its commercial resilience. From this perspective, CanSinoBIO’s globalization strategy is evolving. Overseas markets are no longer merely destinations for mature products, but are increasingly becoming markets in which products, technologies and industrial capabilities can jointly create value. For an innovative vaccine company, this shift from “exporting products” to “exporting capabilities and systems” creates greater room for long-term growth in its overseas business. Portfolio Upgrades Strengthen the Commercial Foundation Sustained overseas expansion is underpinned by a stable product portfolio and strong technological capabilities. According to the Company’s interim report, domestic revenue continued to grow despite factors such as changes in value-added tax, reflecting opportunities created by ongoing innovation. Menhycia(R), China’s first quadrivalent meningococcal conjugate vaccine, expanded its indicated population in February to children aged 3 months to 6 years, broadening its addressable population. Meanwhile, iPneucia(R), a 13-valent pneumococcal conjugate vaccine featuring dual-carrier technology (CRM197/TT), offers a differentiated option for pediatric pneumococcal disease prevention in China. Since its launch in September 2025, iPneucia(R) has continued to expand market access and is now available in nearly 30 provincial-level markets across China. From meningococcal disease to pneumococcal disease, CanSinoBIO is using innovative products to address vaccine segments that continue to offer meaningful unmet demand. As traditional vaccine categories face pressure on volumes, structural growth driven by product and technology upgrades is providing important support for the Company’s commercial resilience. More importantly, the product-development and industrialization capabilities established in the domestic market also provide a foundation for overseas expansion. For an innovative vaccine company, successful commercialization in China not only broadens revenue sources, but also validates the manufacturing, quality-control and supply systems required to replicate and extend those capabilities into international markets. Domestic product upgrades and overseas business growth are thereforeclosely connected rather than separate. The former provides the foundation in products and technologies, while the latter expands the geographic boundaries within which those products can realize their value. Multi-Layered Pipeline Takes Shape to Support Future Growth For an innovative vaccine company, long-term growth depends not only on the commercial performance of existing products, but also on the ability to maintain a steady flow of new products. By pursuing continued ramp-up of marketed products, advancing products under regulatory review and developing next-generation candidates, CanSinoBIO is building a more sustainable and well-sequenced product pipeline. Tripecia(R) (DT3cP Infant), CanSinoBIO’s three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received NDA approval in April 2026, becoming the first approved three-component DTP vaccine in China. In August 2026, the first commercial batches received the Certificate for Batch Release of Biological Products. Provincial tendering and market-access processes are progressing in an orderly manner, and the product has begun entering the market supply stage. While Tripecia(R) represents an upgrade in pertussis vaccination for infants, the Td5cp vaccine for adolescents and adults — which has also been granted Priority Review status — is expected to extend CanSinoBIO’s pertussis vaccine portfolio to a broader population. The New Drug Application for Td5cp has been accepted by China’s National Medical Products Administration (NMPA). In addition, CanSinoBIO’s independently developed Adsorbed Tetanus Vaccine, Tetcia(R), has been formally approved, further strengthening the Company’s adult vaccine portfolio. From infants to adolescents and adults, and from individual products to a multi-product portfolio, this strategy is broadening the foundation for future commercial growth. In pneumococcal vaccines, CanSinoBIO’s 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV24) formally initiated Phase I/II clinical trials in May 2026, and participant enrollment across different cohorts is progressing as planned. At the same time, the Company continues to advance development of its DT3cP-Hib-MCV4 combination vaccine, extending its portfolio toward increasingly multivalent and combination vaccine formats. Over the longer term, CanSinoBIO is continuing to build its mRNA platform and explore applications in preventive vaccines and therapeutic biologics. The Company is conducting early-stage research into mRNA applications for glioblastoma, rhabdomyosarcoma and cervical cancer, while also exploring in vivo CAR therapies. These programs remain at an early stage, with the Company continuing to assess the potential of mRNA and related technologies in disease treatment. Additionally, on August 25, CanSinoBIO announced that its subsidiary, CanSino Shanghai, had entered a strategic collaboration with deepGeneAI on mRNA therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the development and commercialization of personalized mRNA therapeutic cancer vaccines. These pipeline programs represent extensions of CanSinoBIO’s existing technology platforms and product-development experience. The Company’s core platforms — including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, as well as formulation and delivery technologies — provide a foundation for continued product iteration and technology translation. Innovation Supports Long-Term Development Viewed in the context of its 2026 interim results, CanSinoBIO’s story is not simply one of revenue growth. Against a changing domestic vaccine demand structure, innovative products have continued to deliver solid commercial performance, demonstrating the resilience created by product upgrades. Overseas business model expanded beyond finished-product exports to include technology collaboration and local manufacturing capabilities, indicating that international markets are becoming a new source of growth. At the same time, Tripecia(R) has entered the market supply stage, the Td5cp vaccine for adolescents and adults is progressing through regulatory review, and pipeline programs including PCV24, multivalent and combination vaccines, and mRNA technologies continue to advance, providing both product succession and technology reserves for the future. These three pathways ultimately point to the same growth logic: domestic innovation capabilities form the product foundation, overseas expansion broadens the commercial opportunity, and sustained R&D determines whether growth can continue over the long term. In an environment where demand for traditional vaccines is under pressure and industry competition is intensifying, growth is increasingly shifting away from reliance on product-volume expansion alone and toward a model jointly driven by product upgrades, technological innovation and global markets. For CanSinoBIO, continued growth in the overseas business is providing increasingly visible financial evidence of this transition. As more innovative products enter the market, more mature products expand overseas and the Company’s technical capabilities extend further into international value chains, CanSinoBIO’s growth runway is expanding from a single domestic market to the global market. For the Company, internationalization is not only about broadening geographic reach; it is also an important pathway for innovative products and technologies to realize greater commercial value while contributing to global public health.
  8. HealthcareVVater LLCVVater Expands Global Presence Through New Partnership in Asia-Pacific and the Middle EastAUSTIN, TX, Aug 27, 2026 - VVater, America's Next Water Company and the world's premier innovator in advanced water treatment solutions, today announced an expanded international presence across Asia-Pacific Middle East (APME) as the company continues to scale its innovative water treatment technology globally and support new sectors. Via a new partnership agreement, VVater APME will be established. This newly formed venture will bring VVater's technology to a wide range of markets and strategic customers around the world as water scarcity, water quality, regulatory expectations and long-term water stewardship become increasingly important drivers of operational resilience and economic performance. VVater APME is a partnership formed between VVater and Ecosafe International, a regionally recognised water risk management and water stewardship consultancy, which supports organisations to navigate their water journey through governance, assurance, risk reduction and practical innovation. With an extensive track record supporting organisations including BHP, Rio Tinto, Chevron, Shell, JLL and NEOM, Ecosafe advises governments, mining operators, healthcare and industrial organisations on achieving safer, more sustainable and more resilient water outcomes across APME. VVater APME will operate with dedicated sector exclusivity in Australia, New Zealand, Saudi Arabia, Qatar and the UAE. "What drew us to this partnership is how much overlap there already was," said Kevin Gast, CEO and Chairman of VVater. "Ecosafe has spent years building trust with operators in some of the toughest water environments in the world. Pairing that with our technology means we can move faster into markets that badly need it." "For years we've watched clients wrestle with sourcing credible, provable water treatment technology once a risk assessment tells them what they're up against," said Ryan Milne, Founder of Ecosafe International. "This partnership closes a critical gap for us. We've always helped clients understand and govern water risk. Now we can combine that trusted advisory capability with proven technology solutions that accelerate the transition from water risk to water certainty." VVater APME is designed with a defined path to expand into installation, operations, and eventually in-territory manufacturing, creating long-term capability and supporting regional water security outcomes as the partnership matures. The agreement gives VVater APME access to VVater's full suite of proprietary technology, led by the Farady Reactor, a breakthrough in water treatment. Wherever it's deployed, from remote, self-managed water systems and mine sites to municipal water systems and industrial plants, the Farady Reactor transforms wastewater, sewage and drinking water alike, offering a glimpse of what next-generation water infrastructure can look like. VVater APME is the latest step in the company's international growth, following recognition from TIME, CES and Fast Company, and deployments with partners including Nestle and the City of Bastrop, Texas. The agreement reflects VVater's continued push to bring advanced treatment and reuse technology into markets facing mounting water stress. About VVater VVater is America's Next Water Company, delivering the future of purification through its award-winning Farady Reactor (Time Best Invention Award 2025, CES Best of Innovation 2025, World Future Award 2025. The first company in history to win all 3 in 1 year achieving a Triple Crown), proprietary ALTEP (Advanced Low Tension Electroporation Process), Advanced Dissolved Air Flotation, and Micro & Nano Bubble technologies. Unlike outdated chemical, filtration, and membrane systems, VVater's electric-field breakthroughs eliminate microplastics, microorganisms, and other contaminants with record retention times, without producing toxic byproducts or requiring costly consumables. With over 4.3B gallons treated and validation from global leaders, VVater is scaling into municipal drinking water and wastewater, DPR/IPR, onsite reuse for data centers, commercial buildings, and resorts, residential purification, and consumer health water, delivering a 60% smaller footprint, 40% CapEx savings, 80% OpEx savings, and 40% less energy use. For more information, please visit www.vvater.com. Contact Information VVATER Media Office Global Media Room [email protected] Nicholas Koulermos [email protected] SOURCE: VVater LLC
  9. HealthcareConavi Medical Reports Fiscal Third Quarter 2026 Results and Operational HighlightsConavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended June 30, 2026 (“Fiscal Q3 2026”).
  10. FinancePerma-Pipe International Holdings, Inc.Perma-Pipe Announces Closing of Global Credit Facility of Up to $139 MillionTHE WOODLANDS, Texas, August 27, 2026--Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) ("Perma-Pipe" or the "Company"), a leading global provider of engineered piping and leak detection solutions for energy, infrastructure and industrial markets, today announced the closing of a new global credit facility with J.P. Morgan consists of a $75.0 million revolving credit facility and a $14.0 million term loan facility, and allows the Company access to an additional $50.0 million in incremental
  11. AIUniphoreUniphore and Tech Mahindra Partner to Deliver an Agentic AI Factory for the EnterprisePALO ALTO, Calif., August 27, 2026--Uniphore and Tech Mahindra partner to deliver an Agentic AI Factory for the enterprise.
  12. AIWatch & Clock Fair, Salon de TIME return this SeptemberThe 45th Hong Kong Watch & Clock Fair and the 14th Salon de TIME, jointly organised by the Hong Kong Trade Development Council (HKTDC), Hong Kong Watch Manufacturers Association Limited, and the Federation of Hong Kong Watch Trades & Industries Limited, will be held from 1 to 5 September at the Hong Kong Convention and Exhibition Centre (HKCEC). Salon de TIME will be fully open to the public throughout the event. The 45th HKTDC Hong Kong Watch & Clock Fair and 14th Salon de TIME take place from 1 to 5 September at the Hong Kong Convention and Exhibition Centre. Introducing fair highlights at a press conference are Smilely Lam, HKTDC Associate Executive Director (fifth from the left), SK Chong (fourth from the right) and Frankie Lam (fourth from the left), Co-Chairmen, HKTDC Hong Kong Watch & Clock Fair Organising Committee 2026, and celebrity Joey Thye (fifth from the right). Under the theme “Sparkling Moments Through Time”, the two fairs are expected to attract more than 630 exhibitors from 16 countries and regions, showcasing a wide range of watches, clocks and related products to meet evolving market trends and consumer demand. The Click2Match AI-powered business matching platform has been available since 25 August and will remain open until 12 September, enabling exhibitors and buyers from around the world to connect and conduct business discussions online during and beyond the physical fairs. Hong Kong Watch & Clock Fair marks 45th Milestone HKTDC Associate Executive Director Smilely Lam said: “The Hong Kong Watch & Clock Fair and Salon de TIME together form the world's largest one-stop watch and clock marketplace. As the Hong Kong Watch & Clock Fair celebrates its 45th edition this year, the two fairs are continuing to grow in both international reach and diversity, leveraging Hong Kong’s strengths as an international trading hub and Asia’s premier sourcing centre for watches and clocks. This year’s fairs welcome, for the first time, a pavilion from Hengyang, Hunan Province, alongside group pavilions from France, Switzerland, Guangzhou and Taiwan. New exhibitors from Norway, Singapore and the US are joining this year's fair, further strengthening the international profile of the fairs. Salon de TIME is expected to feature more than 150 global brands, reaching a new post-pandemic high. Participation from Hong Kong brands and Guochao-inspired brands has increased by more than 20%, while more brands from Italy, the United Kingdom and the US are joining, alongside the debut of Singaporean brands. This fully demonstrates Hong Kong’s unique role as an important bridge connecting the Chinese Mainland with international markets, as well as the global watch industry’s confidence in the Hong Kong market.” According to the latest trade statistics, Hong Kong is the world’s largest importer and second largest exporter of wristwatches. In the first seven months of this year, the total export value of watches reached approximately HK$30.5 billion, representing a 7.8% year-on-year increase. Several other Hong Kong export markets recorded double-digit growth, including Germany (+21%), Switzerland (+25%) and the United Arab Emirates (+91%). In addition, the watch industry’s export confidence index rose from 50.4 to 51.9 in the second quarter, reflecting the industry’s cautiously optimistic outlook for exports. Microbrand participation doubles, bringing greater diversity to the fair Located in Hall 3FG, Salon de TIME features six themed zones: World Brand Piazza, Chic & Trendy, Craft Treasure, Renaissance Moment, Wearable Tech, and Microbrands. The Microbrands zone has attracted 29 brands from eight countries and regions, with both the number of participating brands and the number of represented countries and regions doubling compared with last year. World Brand Piazza showcases prestigious international watch brands For the 16th consecutive year, the World Brand Piazza zone is organised in partnership with Prince Jewellery & Watch, featuring limited-edition and rare timepieces from some of the world’s most prestigious watch brands. This year, Prince Jewellery & Watch will showcase exceptional creations from six internationally renowned brands: Baume & Mercier, Corum, DeWitt, Franck Muller, Montblanc and Sarcar. World Brand Piazza will feature a selection of limited-edition and highly collectible timepieces. Among the highlights, Franck Muller will present a ladies’ watch created in collaboration with French street artist Jisbar, marking the second partnership between the two parties. The brand will also host a product introduction seminar on 2 September titled “Franck Muller 2026 WPHH Novelties ‘Vanguard Lady Crazy Hours Jisbar’”. Meanwhile, Sarcar has specially created a unique platinum version of its Medusa timepiece exclusively for the World Brand Piazza. The one-of-a-kind watch is set with 228 diamonds, complemented by red garnets and green agates, showcasing exceptional high jewellery craftsmanship. Two marquise-cut diamonds are used to represent Medusa’s eyes. At the same time, the signature snake-hair motif extends seamlessly from the dial to the case and lugs, all meticulously sculpted from solid gold, offering the charm of ancient Roman stone sculptures of beautiful women. The Renaissance Moment zone will also welcome the debut appearance of WOLF, the luxury watch storage box and winder brand from the United Kingdom. Built around the concept of preserving heritage, WOLF provides professional care solutions for high-end mechanical timepieces. On the opening day of the fair (1 September), the brand will unveil its latest innovation, The Rocket, the world's most compact travel watch winder, highlighting WOLF's commitment to innovative design and exceptional craftsmanship. Guochao timepieces showcase the strength of Chinese watchmaking Designs incorporating traditional Chinese cultural elements have gained strong market appeal in recent years. This year, Salon de TIME will bring together five leading independent watchmakers from the Chinese Mainland, all of whom will attend the fair in person. The Académie Horlogère des Créateurs Indépendants (AHCI) which is widely regarded as one of the most prestigious independent watchmaking institutions, maintains exceptionally stringent membership requirements. Currently, only four AHCI members are from the Chinese Mainland, and this year's exhibition will feature three of them including Xushu Ma, who was the first watchmaker from the Chinese Mainland admitted to the association, as well as Zehua Tan and Lin Yong Hua. The opportunity to see such a distinguished line-up in one place is particularly rare. In addition, several Guochao-inspired brands and Chinese watchmakers will showcase their outstanding creations. Highlights include: Chinese watchmaker Qian Guobiao will present the limited-edition AB-05S “Skylight Sun”, restricted to just 18 pieces worldwide. The self-developed AB-05 manual-winding movement powers the timepiece. At the same time, its semi-skeletonized dial reveals the balance wheel and gear train, highlighting the watch's intricate mechanics and technical expertise. Shanghai Watch will present the ORIGINATE Collection A623 Revival Watch, a modern recreation of China’s first calendar watch, modelling after the original A623 timepiece worn for many years by Zhou Enlai, the first Premier of the People’s Republic of China. The brand will also unveil the Hong Kong Exclusive Edition featuring two interchangeable straps in grey and green, with colours inspired by the Zhongshan suits frequently worn by Premier Zhou, evoking a spirit and memory that transcend generations. Award-winning timepieces showcase innovation and craftsmanship This year’s fair brings together award-winning timepieces, highlighting the watch industry’s pursuit of technical excellence and design innovation. Highlights include: AGELOCER’s 29.51-Day MoonPhase Original Astronomer reimagines the traditional moon phase display by featuring an industry-first 28.5mm oversized moon phase aperture. Blending astronomical imagery with mechanical aesthetics, the timepiece has earned nine international design awards, including the German Design Award 2022, MUSE Design Awards Gold 2023, and European Design Award 2023. Making its debut at the exhibition, Singaporean brand Vario will present the Vario VERSA Reversible Dual Time Watch. With an innovative reversible case design, the watch features two independent dials, each showing a different time zone. Users can easily switch between the two displays, making it a practical companion for international travellers. The unique design earned the watch the 2025 iF Design Award. Collaborations, innovation and limited-edition collectibles cater to diverse market tastes The fairs will also feature collaborative, limited-edition, and debut timepieces, showcasing different styles and innovations to meet evolving consumer preferences, including: LINK2CARE has partnered with Swiss watch brand MARVIN to launch a luxury smartwatch that integrates LINK2CARE’s patented leather strap with concealed medical-grade vital sensor. The watch provides comprehensive health monitoring capabilities, including real-time tracking of mental resilience and stress levels, with data displayed directly on the watch dial. This year’s two major overseas pavilions, the Swiss Independent Watchmakers Pavilion (SIWP) and France’s Francéclat, together with other European exhibitors, will bring together around 80 brands from across Europe. Among the highlights, Swiss watchmaker Pilo & Co Genève will showcase the Corleone Mini Collection, created to celebrate the brand’s 25th anniversary. Reimagining the iconic Corleone design as a refined ladies’ timepiece, the collection blends elegance with contemporary sophistication, with each colour variant limited to just 10 pieces worldwide. Several product zones showcase industry strength; Time Tunnel celebrates 45th edition The Hong Kong Watch & Clock Fair, to be held in Hall 1, features seven dedicated product zones. Among them, Pageant of Eternity will showcase premium finished watches from Original Equipment Manufacturers (OEM) and Original Design Manufacturers (ODM). One example is Hong Kong exhibitor Time Grand Ltd, which has more than 20 years of experience in product development, engineering design, and manufacturing services for global watch brands. Through its network of partnerships with Swiss watchmaking companies, the firm offers one-stop watchmaking solutions, demonstrating the strength of Hong Kong’s watch industry in connecting international watchmaking markets. Other zones include Complete Watches, Clocks, Machinery & Equipment, Packaging & Display, Parts, Components & Accessories. To celebrate the 45th edition of the Hong Kong Watch & Clock Fair, organisers will present a special “Time Tunnel” exhibition, taking visitors on a journey through three key stages in the fair’s evolution since its debut in 1982. The exhibition will revisit the period from the 1980s to the 1990s, when the fair established itself as a major global sourcing platform for the watch and clock industry. It then traces the transformation of Hong Kong’s watch industry between 2000 and 2020, as the sector evolved from OEM manufacturing toward brand development, with the fair becoming an important platform for industry promotion, networking, and exchange. The final section covers the period from 2020 to the present, when the fair expanded beyond manufacturing, sourcing, and brand promotion. Through cross-sector collaboration and the integration of resources from different industries, it has evolved into a multifaceted platform that brings together craftsmanship, design, technology, lifestyle, culture and consumer engagement, reflecting the continuous transformation of both the watch industry and the fair itself. Experts to share insights on emerging global watch industry trends More than 40 events will take place throughout the fair, including forums, seminars, watch parades, and networking activities, giving industry professionals valuable insights into the latest market developments and business opportunities. On the opening day (1 September), the Hong Kong International Watch Forum will bring together leaders of watch industry associations from Chinese Mainland, Germany, France, Switzerland, Japan and Korea to share the latest trade statistics and industry trends in their respective markets. Speakers will also explore new opportunities arising from the convergence of traditional watchmaking craftsmanship and technological innovation. On the second day (2 September), the Asian Watch Conference will be held under the theme “Hong Kong as the hub of International Watch Trades”. Senior analysts from international research firm Euromonitor International (Hong Kong) will present the latest developments in the global watch market. Representatives from online watch resale platform Chrono24 will discuss how businesses can connect with global demand through digital channels. At the same time, speakers from Lazada HK will share insights on how to leverage e-commerce platforms to accelerate market expansion and reach new customer segments. The 43rd Hong Kong Watch & Clock Design Competition, jointly organised by the HKTDC, the Hong Kong Watch Manufacturers Association Limited, and the Federation of Hong Kong Watch Trades & Industries Limited, aims to promote watch design exchanges and nurture local talent. This year, the themes for the Open Group and Student Group are “Transcending Time” and “Contours of the Breeze” respectively. The competition will continue to feature The Made-to-sell Award, recognising student entries with outstanding commercial potential. The award presentation ceremony will be held on 5 September at the fair’s event stage, with celebrity Joey Thye attending as a guest. Public activities and lucky draws offer an exciting visitor experience Salon de TIME will host a variety of special activities and luxury watch showcases open to the public. Among the highlights, renowned watch art specialist and collector Labeg will lead a workshop on 4 September, demonstrating how to craft wristwatches from corrugated cardboard. This year, the exhibition also introduces the “Time Arena” activity zone, combining sports and luxury watch elements to offer visitors a fresh and interactive experience. A key feature will be the “Watch2Care Smart x Lifestyle Experience Days”, taking place from 4 to 5 September, featuring a range of interactive activities. Visitors will also have the opportunity to try pickleball, one of the fastest-growing sports in recent years. Other highlights include yoga and body mobility sessions, watch parades, and product launch events. Memorigin will unveil the Verdant Resonance Tourbillon watch, and invite several celebrity guests to attend its activities, including celebrity Vic Teo, Hong Kong basketball star Wong Lut Yiu, and renowned face-changing performer Hathor Wai. A Lucky Draw will be held daily throughout the fair, offering visitors the chance to win premium watches sponsored by brands including Memorigin, SAGA, ELMER INGO, Allied Asia Enterprise (PVT) Limited, Alexus Christy, Claudia Koch and FOKSY. In addition, CENTRESTAGE, Hong Kong’s premier fashion event, will take place concurrently at the HKCEC from 2 to 5 September, bringing together fashion brands and designer collections from around the world. The co-location of the events will create strong synergies, allowing visitors to explore the latest collections from more than 400 watch and fashion brands under one roof. Photo download: https://bit.ly/4xqIloM The 45th HKTDC Hong Kong Watch & Clock Fair and 14th Salon de TIME take place from 1 to 5 September at the Hong Kong Convention and Exhibition Centre. Introducing fair highlights at a press conference are Smilely Lam, HKTDC Associate Executive Director (fifth from the left), SK Chong (fourth from the right) and Frankie Lam (fourth from the left), Co-Chairmen, HKTDC Hong Kong Watch & Clock Fair Organising Committee 2026, and celebrity Joey Thye (fifth from the right). Celebrity Joey Thye to host exclusive watch unboxing session, showcasing eight timepieces. The World Brand Piazza, organised in partnership with Prince Jewellery & Watch for the 16th consecutive year, has long been one of the exhibition’s signature attractions and remains a favourite among watch collectors. This year, Prince Jewellery & Watch is presenting luxury creations from six internationally renowned watch brands, including the Vanguard Lady Crazy Hours Jisbar (left), a collaboration between Franck Muller and French street artist Jisbar, as well as a unique platinum version of the Medusa timepiece (right) created exclusively for the exhibition by Sarcar. Chinese watchmaker Qian Guobiao will present the limited-edition AB-05S “Skylight Sun”, restricted to just 18 pieces worldwide. The self-developed AB-05 manual-winding movement powers the timepiece. At the same time, its semi-skeletonized dial reveals the balance wheel and gear train, highlighting the watch's intricate mechanics and technical expertise. AGELOCER’s 29.51-Day MoonPhase Original Astronomer reimagines the traditional moon phase display by featuring an industry-first 28.5mm oversized moon phase aperture. Blending astronomical imagery with mechanical aesthetics, the timepiece has earned nine international design awards, including the German Design Award 2022, MUSE Design Awards Gold 2023, and European Design Award 2023. Vario VERSA Reversible Dual Time Watch’s innovative reversible case design, the watch features two independent dials, each showing a different time zone. Users can easily switch between the two displays, making it a practical companion for international travellers. The unique design earned the watch the 2025 iF Design Award. LINK2CARE has partnered with Swiss watch brand MARVIN to launch a luxury smartwatch that integrates LINK2CARE’s patented leather strap with concealed medical-grade biometric sensors. The watch provides comprehensive health monitoring capabilities, including real-time tracking of resilience and stress levels, with data displayed directly on the watch dial. Memorigin will unveil the “Verdant Resonance Tourbillon watch”, inspired by the refined lifestyle of ancient Chinese scholars, particularly the tradition of playing the zither while enjoying incense. It combines Chinese cultural aesthetics with contemporary haute horlogerie craftsmanship. The 43rd Hong Kong Watch & Clock Design Competition features two categories, the Open Group and the Student Group, with design themes of “Transcending Time” and “Contours of the Breeze” respectively. Award-winning and shortlisted entries will be exhibited throughout the fair, showcasing the creativity and design talent of Hong Kong’s emerging and established watch designers. Photo shows representatives of the watch and clock industry together with the competition judges. Websites: Hong Kong Watch & Clock Fair: https://www.hktdc.com/event/hkwatchfair/en Salon de TIME: https://www.hktdc.com/event/te/en Media enquiries Please contact the HKTDC’s Communications & Public Affairs Department: Johnny Tsui Tel: (852) 2584 4395 Email : [email protected] About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.